Provided below are an analyst's forecasts of revenue, net operating profit after tax (NOPAT), and net operating assets (NOA) as of 12/31/2020 for Abbott Laboratories. Forecast Horizon Period 2022 2023 $34,608.0 $36,684.5 $38,885.5 $41,218.7 $43,691.8 $4,774.4 $5,060.9 $5,364.5 $5,686.4 $6,027.6 $44,579.0 $47,253.7 $50,089.0 $53,094.3 $56,280.0 ($ millions) Reported 2020 2021 Revenue: NOPAT: NOA: 2024 Terminal Period $44,565.6 $6,148.1 $57,405.6 The following additional information is provided (dollar and share amounts in millions). Common shares outstanding: 1,771.230 Net nonoperating obligations (NNO): $11,576.0 Noncontrolling interest (NCI): $219.0 Preferred stock: $0.0 WACC: 4.0% Terminal growth: 2.0%
Provided below are an analyst's forecasts of revenue, net operating profit after tax (NOPAT), and net operating assets (NOA) as of 12/31/2020 for Abbott Laboratories. Forecast Horizon Period 2022 2023 $34,608.0 $36,684.5 $38,885.5 $41,218.7 $43,691.8 $4,774.4 $5,060.9 $5,364.5 $5,686.4 $6,027.6 $44,579.0 $47,253.7 $50,089.0 $53,094.3 $56,280.0 ($ millions) Reported 2020 2021 Revenue: NOPAT: NOA: 2024 Terminal Period $44,565.6 $6,148.1 $57,405.6 The following additional information is provided (dollar and share amounts in millions). Common shares outstanding: 1,771.230 Net nonoperating obligations (NNO): $11,576.0 Noncontrolling interest (NCI): $219.0 Preferred stock: $0.0 WACC: 4.0% Terminal growth: 2.0%
Essentials Of Investments
11th Edition
ISBN:9781260013924
Author:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Chapter1: Investments: Background And Issues
Section: Chapter Questions
Problem 1PS
Related questions
Question
![Provided below are an analyst’s forecasts of revenue, net operating profit after tax (NOPAT), and net operating assets (NOA) as of 12/31/2020 for Abbott Laboratories.
| ($ millions) | Reported 2020 | 2021 | 2022 | 2023 | 2024 | Terminal Period |
|-------------------|--------------|-----------|-----------|-----------|-----------|-----------------|
| Revenue: | $34,608.0 | $36,684.5 | $38,885.5 | $41,218.7 | $43,691.8 | $44,565.6 |
| NOPAT: | $4,774.4 | $5,060.9 | $5,364.5 | $5,686.4 | $6,027.6 | $6,148.1 |
| NOA: | $44,579.0 | $47,253.7 | $50,089.0 | $53,094.3 | $56,280.0 | $57,405.6 |
The following additional information is provided (dollar and share amounts in millions):
- Common shares outstanding: 1,771.230
- Net nonoperating obligations (NNO): $11,576.0
- Noncontrolling interest (NCI): $219.0
- Preferred stock: $0.0
- WACC: 4.0%
- Terminal growth: 2.0%
Use the discounted cash flow (DCF) method to answer the following questions. Do not round intermediate calculations. All values other than per-share amounts are shown in millions.
| Question | Answer |
|---------------------------------------------------------------------------------------------------------------------------------|---------------------|
| According to the DCF model, what is the total value of the firm? | $224,108.3 |
| According to the DCF model, what is the value per share of common stock? | $119.87 |
| The company’s stock closed at $123.04 on 02/19/2021, the date the 10-K was filed with the SEC. In comparing your valuation estimate (also known as ‘intrinsic value’) with the actual stock price, was the stock overvalued or undervalued, and why? | Over](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2Fd21fc526-74bd-47ca-ba0a-33a8c2012020%2Fc8540208-0493-48a1-b47e-cdf426e308b1%2Ftishmma_processed.png&w=3840&q=75)
Transcribed Image Text:Provided below are an analyst’s forecasts of revenue, net operating profit after tax (NOPAT), and net operating assets (NOA) as of 12/31/2020 for Abbott Laboratories.
| ($ millions) | Reported 2020 | 2021 | 2022 | 2023 | 2024 | Terminal Period |
|-------------------|--------------|-----------|-----------|-----------|-----------|-----------------|
| Revenue: | $34,608.0 | $36,684.5 | $38,885.5 | $41,218.7 | $43,691.8 | $44,565.6 |
| NOPAT: | $4,774.4 | $5,060.9 | $5,364.5 | $5,686.4 | $6,027.6 | $6,148.1 |
| NOA: | $44,579.0 | $47,253.7 | $50,089.0 | $53,094.3 | $56,280.0 | $57,405.6 |
The following additional information is provided (dollar and share amounts in millions):
- Common shares outstanding: 1,771.230
- Net nonoperating obligations (NNO): $11,576.0
- Noncontrolling interest (NCI): $219.0
- Preferred stock: $0.0
- WACC: 4.0%
- Terminal growth: 2.0%
Use the discounted cash flow (DCF) method to answer the following questions. Do not round intermediate calculations. All values other than per-share amounts are shown in millions.
| Question | Answer |
|---------------------------------------------------------------------------------------------------------------------------------|---------------------|
| According to the DCF model, what is the total value of the firm? | $224,108.3 |
| According to the DCF model, what is the value per share of common stock? | $119.87 |
| The company’s stock closed at $123.04 on 02/19/2021, the date the 10-K was filed with the SEC. In comparing your valuation estimate (also known as ‘intrinsic value’) with the actual stock price, was the stock overvalued or undervalued, and why? | Over
Expert Solution
![](/static/compass_v2/shared-icons/check-mark.png)
This question has been solved!
Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.
This is a popular solution!
Trending now
This is a popular solution!
Step by step
Solved in 3 steps with 2 images
![Blurred answer](/static/compass_v2/solution-images/blurred-answer.jpg)
Knowledge Booster
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, finance and related others by exploring similar questions and additional content below.Recommended textbooks for you
![Essentials Of Investments](https://compass-isbn-assets.s3.amazonaws.com/isbn_cover_images/9781260013924/9781260013924_smallCoverImage.jpg)
Essentials Of Investments
Finance
ISBN:
9781260013924
Author:
Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:
Mcgraw-hill Education,
![FUNDAMENTALS OF CORPORATE FINANCE](https://www.bartleby.com/isbn_cover_images/9781260013962/9781260013962_smallCoverImage.gif)
![Financial Management: Theory & Practice](https://www.bartleby.com/isbn_cover_images/9781337909730/9781337909730_smallCoverImage.gif)
![Essentials Of Investments](https://compass-isbn-assets.s3.amazonaws.com/isbn_cover_images/9781260013924/9781260013924_smallCoverImage.jpg)
Essentials Of Investments
Finance
ISBN:
9781260013924
Author:
Bodie, Zvi, Kane, Alex, MARCUS, Alan J.
Publisher:
Mcgraw-hill Education,
![FUNDAMENTALS OF CORPORATE FINANCE](https://www.bartleby.com/isbn_cover_images/9781260013962/9781260013962_smallCoverImage.gif)
![Financial Management: Theory & Practice](https://www.bartleby.com/isbn_cover_images/9781337909730/9781337909730_smallCoverImage.gif)
![Foundations Of Finance](https://www.bartleby.com/isbn_cover_images/9780134897264/9780134897264_smallCoverImage.gif)
Foundations Of Finance
Finance
ISBN:
9780134897264
Author:
KEOWN, Arthur J., Martin, John D., PETTY, J. William
Publisher:
Pearson,
![Fundamentals of Financial Management (MindTap Cou…](https://www.bartleby.com/isbn_cover_images/9781337395250/9781337395250_smallCoverImage.gif)
Fundamentals of Financial Management (MindTap Cou…
Finance
ISBN:
9781337395250
Author:
Eugene F. Brigham, Joel F. Houston
Publisher:
Cengage Learning
![Corporate Finance (The Mcgraw-hill/Irwin Series i…](https://www.bartleby.com/isbn_cover_images/9780077861759/9780077861759_smallCoverImage.gif)
Corporate Finance (The Mcgraw-hill/Irwin Series i…
Finance
ISBN:
9780077861759
Author:
Stephen A. Ross Franco Modigliani Professor of Financial Economics Professor, Randolph W Westerfield Robert R. Dockson Deans Chair in Bus. Admin., Jeffrey Jaffe, Bradford D Jordan Professor
Publisher:
McGraw-Hill Education